SGMT

Sagimet Biosciences Inc. - Series A

3.99 USD

Last updated Dec 8, 16:43 UTC

Yesterday HIGH

$4.17

Yesterday LOW

$3.92

52w HIGH

$18.33

52w LOW

$2.13

EPS

-0.35

PE

-11.40

Next Earnings

Feb 11, 2024

Overview News Insider Transactions Government Trades

Sagimet Biosciences Inc. - Series A stock is up 13.68% since 30 days ago. The next earnings date is Feb 11, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 1 December’s closed higher than November. 100% of analysts rate it a buy.

We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. We were incorporated in Delaware in December 2006 under the name 3-V Biosciences, Inc., and changed our name to Sagimet Biosciences Inc. in August 2019. Our principal executive offices are located at 155 Bovet Road, Suite 303, San Mateo, California.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

www.sagimet.com

richadhand@benzinga.com

Tue Aug 8, 2023

Piper Sandler Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price Target of $67

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Overweight rating and announces Price Target of $67.
richadhand@benzinga.com

Tue Aug 8, 2023

JMP Securities Initiates Coverage On Sagimet Biosciences with Market Outperform Rating, Announces Price Target of $30

JMP Securities analyst Jonathan Wolleben initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform rating and announces Price Target of $30.
richadhand@benzinga.com

Tue Aug 8, 2023

Goldman Sachs Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $33

Goldman Sachs analyst Andrea Tan initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Buy rating and announces Price Target of $33.
Happy Mohamed

Fri Jul 14, 2023

Sagimet Biosciences Shares Open For Trade At $15.72; IPO Priced At $16/Share
Benzinga Newsdesk

Fri Jul 14, 2023

Sagimet Biosciences IPO Indicating $16 On 239K Shares; IPO Priced At $16/Share On 5.3125M Shares
Benzinga Newsdesk

Fri Jul 14, 2023

Sagimet Biosciences IPO Indicating $17 On 216K Shares; IPO Priced At $16/Share On 5.3125M Shares
Benzinga Newsdesk

Fri Jul 14, 2023

Sagimet Biosciences IPO Indicating $17.50 On 131K Shares; IPO Priced At $16/Share On 5.3125M Shares
Happy Mohamed

Fri Jul 14, 2023

Sagimet Biosciences IPO Indicating $17.50 On 87K Shares; IPO Priced At $16/Share On 5.3125M Shares
Benzinga Insights

Thu Jul 13, 2023

Preview: Sagimet Biosciences Inc Set To IPO Tomorrow
Benzinga Newsdesk

Wed Jun 7, 2023

Sagimet Biosciences To Present Interim Data From Phase 2b Trial Of Denifanstat In NASH At EASL Congress 2023

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced that it will present interim data from the FASCINATE-2 Phase

JP Morgan

Tue Dec 5, 09:25

buy

confirm

Advanced Data Unlock

Rozek Elizabeth, General Counsel and CCO

Fri Nov 17, 2023

SGMT Recent Insider Trades and Stock Chart

171,420 shares awarded
Martins Eduardo Bruno, Chief Medical Officer

Fri Nov 17, 2023

SGMT Recent Insider Trades and Stock Chart

89,570 shares awarded
Kemble George, Director

Fri Nov 17, 2023

SGMT Recent Insider Trades and Stock Chart

150,750 shares awarded
Happel David, Director

Fri Nov 17, 2023

SGMT Recent Insider Trades and Stock Chart

624,910 shares awarded
Happel David, Director

Thu Nov 16, 2023

SGMT Recent Insider Trades and Stock Chart

590 shares bought